SPARQL | HTML5 RDFa and Microdata document
  • http://rdf.wikipathways.org/Pathway/WP3242_r125627/Interaction/b8518
    • http://vocabularies.wikipathways.org/gpml#hasComment
      • http://rdf.wikipathways.org/Pathway/WP3242_r125627/Comment/76cf41b64ffaf8d91224dbb37af759f6
  • http://rdf.wikipathways.org/Pathway/WP3242_r125627/Comment/76cf41b64ffaf8d91224dbb37af759f6
    • http://www.w3.org/1999/02/22-rdf-syntax-ns#type
      • http://vocabularies.wikipathways.org/gpml#Comment
    • http://purl.org/dc/terms/isPartOf
      • http://rdf.wikipathways.org/Pathway/WP3242_r125627/Interaction/b8518
    • http://vocabularies.wikipathways.org/gpml#commentText
      • 12225966 (Tissue: muscle) We have recently reported that inhibition of muscle MAPKK1/2 (MEK1/2) abolishes isoproterenol-stimulated NKCC activity and ERK1/2 phosphorylation ( 31 ). 12393899 (Tissue: cortex, CellType: neural) To inhibit the ERK1/2 pathway, we applied PD98059, an inhibitor of MKK1 and MKK2 ( 30 ), which are upstream kinases that phosphorylate and activate ERK1/2.